A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

Clinical trial NCT07187401 · RECRUITING

Trial details

NCT number: NCT07187401
Sponsor: Regeneron Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Paroxysmal Nocturnal Hemoglobinuria (PNH)Persistent Anemia

Start date: 2026-02-11
Primary completion: 2029-11-29
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.